retatrutide ly3437943 phase 2 trial obesity nejm 2023 Early data for demonstrates exceptional weight loss results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading medications currently under Retatrutide Results: 24% Weight Loss
Description
Clinical guidance on switching protocols will emerge post-approval
You want to switch to Saturdays
Nadauld LD, Garcia S, Natsoulis G, Bell JM, Miotke L, Hopmans ES, Xu H, Pai RK, Palm C, Regan JF, Chen H, Flaherty P, Ootani A, Zhang NR, Ford JM, Kuo CJ, Ji HP
Other reported side effects include headache, fatigue, and injection site reactions for injectable preparations
Look for credentials, licenses, and reviews confirming legitimacy
doi: 10.1186/s10020-023-00647-0
